Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 426 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: VEGF Clear all
Completed Phase 2 Interventional Results available

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

NCT00284141
View directory record Official record
Conditions
Pulmonary Diseases, Neoplasms, Lung
Interventions
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 28, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer

NCT01676714
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer
Interventions
Dovitinib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 28, 2026, 9:34 AM EDT
Completed Not applicable Interventional Results available

Avastin for PDR (Proliferative Diabetic Retinopathy)

NCT01270542
View directory record Official record
Conditions
Retinal Detachment, Diabetic Retinopathy
Interventions
Avastin (bevacizumab), Sham injection
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 28, 2026, 9:34 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Role of Adenosine in the Release of VEGF and Cytokines

NCT00580905
View directory record Official record
Conditions
Inflammation
Interventions
Adenosine, Sodium Nitroprusside
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 28, 2026, 9:34 AM EDT
Completed Phase 2 Interventional

Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy

NCT01472510
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Vitreo-Retinal Associates, PC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 28, 2026, 9:34 AM EDT
Terminated Phase 2 Interventional Results available

Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury

NCT04051957
View directory record Official record
Conditions
Kidney Injury, Proteinuria, Hypertension
Interventions
Isosorbide Mononitrate, Placebo oral tablet
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 28, 2026, 9:34 AM EDT
Completed Phase 1 Interventional

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

NCT02665416
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors
Interventions
Selicrelumab, Vanucizumab, Bevacizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 28, 2026, 9:34 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lucentis (Ranibizumab) for Eales' Disease

NCT00384449
View directory record Official record
Conditions
Eales' Disease
Interventions
Ranibizumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 28, 2026, 9:34 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

NCT04195750
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Everolimus
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • La Jolla, California • Santa Rosa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 9:34 AM EDT
Active, not recruiting Phase 2 Interventional

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

NCT02884648
View directory record Official record
Conditions
Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 28, 2026, 9:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 9:34 AM EDT
Completed Phase 4 Interventional Results available

To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

NCT01495221
View directory record Official record
Conditions
AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)
Interventions
Alfilbercept
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 28, 2026, 9:34 AM EDT
Completed Phase 1 Interventional

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

NCT02429843
View directory record Official record
Conditions
Lung Cancer
Interventions
TRC105
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 28, 2026, 9:34 AM EDT
Completed Phase 1 Interventional

PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer

NCT00508586
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
PTC299
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 28, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

NCT00378703
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
558
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 356 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 28, 2026, 9:34 AM EDT
Completed No phase listed Observational

Blood Factors and Diabetic Retinopathy

NCT00005761
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
10 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 9:34 AM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT03802630
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 28, 2026, 9:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

NCT06635785
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
AI-081
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Springdale, Arkansas • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 28, 2026, 9:34 AM EDT
Terminated Phase 4 Interventional Results available

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

NCT04707625
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept Ophthalmic
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 28, 2026, 9:34 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

NCT01994291
View directory record Official record
Conditions
Macular Edema, Diabetic
Interventions
Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 28, 2026, 9:34 AM EDT
Completed Phase 1 Interventional

Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma

NCT00276055
View directory record Official record
Conditions
Sarcoma
Interventions
Gemcitabine, Docetaxel and Bevacizumab
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 28, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

NCT00659555
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib eye drops, Ketoconozole tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 28, 2026, 9:34 AM EDT
Completed Phase 1Phase 2 Interventional

Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)

NCT04125732
View directory record Official record
Conditions
Coronary Artery Disease, Ischemia, Angina Refractory, Cardiovascular Diseases, Heart Diseases
Interventions
AdVEGFXC1
Biological
Lead sponsor
XyloCor Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Stanford, California • Washington D.C., District of Columbia • Daytona Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 28, 2026, 9:34 AM EDT
Not listed Phase 4 Interventional

Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

NCT01857544
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 28, 2026, 9:34 AM EDT